179 related articles for article (PubMed ID: 8478573)
1. [Cardioprotective effect of cromakalim, a K+ channel opener, on isolated globally ischemic and reperfused rat hearts].
Taki H; Masuda Y; Yoshizumi M; Kitagawa T; Katoh I
Nihon Kyobu Geka Gakkai Zasshi; 1993 Mar; 41(3):438-44. PubMed ID: 8478573
[TBL] [Abstract][Full Text] [Related]
2. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
3. Effect of cromakalim on ischemic and reperfused immature heart: experiments with isolated neonatal New Zealand white rabbit hearts.
Shimoe Y; Yoshizumi M; Masuda Y; Kitagawa T; Katoh I
Tokushima J Exp Med; 1996 Dec; 43(3-4):135-41. PubMed ID: 9100462
[TBL] [Abstract][Full Text] [Related]
4. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
5. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
Tosaki A; Engelman DT; Engelman RM; Das DK
J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
[TBL] [Abstract][Full Text] [Related]
7. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.
Grover GJ; Newburger J; Sleph PG; Dzwonczyk S; Taylor SC; Ahmed SZ; Atwal KS
J Pharmacol Exp Ther; 1991 Apr; 257(1):156-62. PubMed ID: 2019983
[TBL] [Abstract][Full Text] [Related]
9. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
10. Ischemic preconditioning in immature hearts: mechanism and compatibility with cardioplegia.
Zhu B; Min S; Long C; Ye T
Chin Med J (Engl); 2003 Feb; 116(2):253-7. PubMed ID: 12775242
[TBL] [Abstract][Full Text] [Related]
11. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
12. Pinacidil pretreatment extends ischemia tolerance of neonatal rabbit hearts.
Feng J; Li H; Rosenkranz ER
J Surg Res; 2000 May; 90(2):131-7. PubMed ID: 10792953
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts.
Tosaki A; Das DK
J Pharmacol Exp Ther; 1997 Jul; 282(1):309-17. PubMed ID: 9223569
[TBL] [Abstract][Full Text] [Related]
14. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle.
Venkatesh N; Stuart JS; Lamp ST; Alexander LD; Weiss JN
Circ Res; 1992 Dec; 71(6):1324-33. PubMed ID: 1423930
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
[TBL] [Abstract][Full Text] [Related]
16. The effects of Na movement on surgical myocardial protection: the role of the Na+-H+ exchange system and Na-channel in the development of ischemia and reperfusion injury.
Liu KX; Yamamoto F; Yamamoto H; Wang T; Zhu Z; Xu R; Zhang S
Ann Thorac Cardiovasc Surg; 2007 Oct; 13(5):301-7. PubMed ID: 17954986
[TBL] [Abstract][Full Text] [Related]
17. K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation.
Ford WR; Lopaschuk GD; Schulz R; Clanachan AS
Br J Pharmacol; 1998 Jun; 124(4):639-46. PubMed ID: 9690854
[TBL] [Abstract][Full Text] [Related]
18. [Cardioprotective effects of cariporide as an adjunct in different cardioplegic solutions: an experiment with rabbits].
Zhou RH; Long C; Liu J; Liu B
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(33):2320-3. PubMed ID: 18036293
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of ischemia/reperfusion injury in isolated rats hearts by the ATP-sensitive potassium channel opener BMS-180448.
Monticello TM; Sargent CA; McGill JR; Barton DS; Grover GJ
Cardiovasc Res; 1996 Jan; 31(1):93-101. PubMed ID: 8849593
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
